V212-011 (Merck zoster): A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy
The proposed indication for this INACTIVATED varicella-zoster virus vaccine is the prevention of Herpes Zoster (SHINGLES) and related complications in immunocompromised patients. Prevention of Herpes Zoster disease (SHINGLES) in this population, including those with Hematologic malignancy or those with Solid Tumor malignancy receiving chemotherapy, represents an area of significant medical need, since these individuals cannot receive the live Herpes Zoster (SHINGLES) vaccine.
Principal Investigator: Ravin Garg, MD. (443) 753-5300
Research Staff: Steven DeMartino, CRCC (443) 481-4390
Elizabeth Egan, RN (443) 481-5811